$ELOX
Eloxx Pharmaceuticals, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018028309 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q1 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.950M $3.390M $490.0K
YoY Change 1114.29% 1440.91% 2.08%
% of Gross Profit
Research & Development $5.415M $4.394M $3.280M
YoY Change 65.09% 86.58% 1070.43%
% of Gross Profit
Depreciation & Amortization $75.00K $21.00K $11.00K
YoY Change 581.82% 250.0% 10.0%
% of Gross Profit
Operating Expenses $11.36M $8.548M $4.000M
YoY Change 184.0% 224.77% 1327.35%
Operating Profit -$11.36M -$8.548M -$4.000M
YoY Change 184.0% 224.77% 80.95%
Interest Expense -$127.4K
YoY Change 172095.95%
% of Operating Profit
Other Income/Expense, Net $199.0K -$43.00K -$40.00K
YoY Change -597.5% -96.97% -109.3%
Pretax Income -$11.16M -$8.590M -$1.267M
YoY Change 780.84% 315.77% -19.48%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.16M -$8.591M -$4.040M
YoY Change 176.26% 220.8% 332.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$318.8K -$312.0K -$613.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q1 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.34M $18.29M $960.0K
YoY Change 5664.58% 7520.83% 231.03%
Cash & Equivalents $55.34M $18.29M $13.54M
Short-Term Investments
Other Short-Term Assets $810.0K $560.0K $80.00K
YoY Change 912.5% 1766.67% -11.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.14M $18.84M $1.040M
YoY Change 5297.88% 6820.25% 173.68%
LONG-TERM ASSETS
Property, Plant & Equipment $345.0K $314.0K $40.00K
YoY Change 762.5% 422.06% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $52.00K $10.00K
YoY Change 420.0% -83.33%
Total Long-Term Assets $397.0K $314.0K $5.550M
YoY Change -92.85% -94.36% -16.29%
TOTAL ASSETS
Total Short-Term Assets $56.14M $18.84M $1.040M
Total Long-Term Assets $397.0K $314.0K $5.550M
Total Assets $56.54M $19.16M $6.590M
YoY Change 757.89% 227.87% -5.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.352M $2.173M $110.0K
YoY Change 1129.09% 1890.91% -21.43%
Accrued Expenses $3.727M $3.478M $260.0K
YoY Change 1333.46% 2101.36% -18.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $710.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.079M $5.651M $1.080M
YoY Change 370.28% 434.39% 129.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.079M $5.651M $1.080M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.080M $5.650M $3.276M
YoY Change 55.05% 73.45% -3.35%
SHAREHOLDERS EQUITY
Retained Earnings -$72.12M -$47.55M -$123.2M
YoY Change -41.47% -60.19%
Common Stock $123.7M $61.06M $514.1K
YoY Change 23950.95% 22580.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $51.46M $13.51M $3.315M
YoY Change
Total Liabilities & Shareholders Equity $56.54M $19.16M $6.591M
YoY Change 757.76% 227.87% -5.98%

Cashflow Statement

Concept 2018 Q3 2018 Q1 2017 Q3
OPERATING ACTIVITIES
Net Income -$11.16M -$8.591M -$4.040M
YoY Change 176.26% 220.8% 332.74%
Depreciation, Depletion And Amortization $75.00K $21.00K $11.00K
YoY Change 581.82% 250.0% 10.0%
Cash From Operating Activities -$8.100M -$5.697M -$575.3K
YoY Change 1307.9% 108.6% 0.28%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $57.00K
YoY Change -22.97%
Acquisitions
YoY Change
Other Investing Activities -$10.00K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$40.00K -$57.00K $0.00
YoY Change -40.63% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.500M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 0.000 $1.500M
YoY Change -99.33% -100.0%
NET CHANGE
Cash From Operating Activities -8.100M -5.697M -$575.3K
Cash From Investing Activities -40.00K -57.00K $0.00
Cash From Financing Activities 10.00K 0.000 $1.500M
Net Change In Cash -8.130M -5.754M $924.7K
YoY Change -979.23% 1467.85% -276.55%
FREE CASH FLOW
Cash From Operating Activities -$8.100M -$5.697M -$575.3K
Capital Expenditures -$30.00K $57.00K
Free Cash Flow -$8.070M -$5.754M
YoY Change 105.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55336000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24049000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
102000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
355000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24506000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
46000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
756000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
56138000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2018Q3 us-gaap Assets
Assets
56535000
CY2017Q4 us-gaap Assets
Assets
24784000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1352000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1530000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3727000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5079000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3423000
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
351000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
274000
CY2018Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
83000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2695000
us-gaap Share Based Compensation
ShareBasedCompensation
9608000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-785000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-4040000
us-gaap Net Income Loss
NetIncomeLoss
-33158000
us-gaap Share Based Compensation
ShareBasedCompensation
38000
us-gaap Depreciation
Depreciation
121000
us-gaap Depreciation
Depreciation
24000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
625000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
401000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-658000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-178000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22307000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9668000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53676000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31231000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11349000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24151000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2250000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55382000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13599000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13538000
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
46000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
61000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3280000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13959000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8230000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
720000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18898000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
123306000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60047000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72118000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38960000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
51456000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1581000
elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
594000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21361000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56535000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24784000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35124844
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27527738
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35124844
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27527738
CY2018Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
8385
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
us-gaap Operating Expenses
OperatingExpenses
33451000
us-gaap Operating Expenses
OperatingExpenses
9811000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33451000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9811000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
293000
us-gaap Net Income Loss
NetIncomeLoss
-10596000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35005979
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4208088
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4206226
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.92
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-12000
us-gaap Interest Expense Debt
InterestExpenseDebt
43000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-740000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1730000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
280000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
11000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5415000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5945000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
11360000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
4000000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11360000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4000000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
199000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-11161000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31485067
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-155000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
103000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21172000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
104000
elox Noncash Acquisition Of Treasury Shares
NoncashAcquisitionOfTreasuryShares
83000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3168000
elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3393000
CY2018Q1 elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
761000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8548000
CY2018Q3 us-gaap Prepaid Insurance
PrepaidInsurance
208000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
242000
CY2018Q3 elox Contract Receivable Current
ContractReceivableCurrent
37000
CY2017Q4 elox Contract Receivable Current
ContractReceivableCurrent
88000
CY2018Q3 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
165000
CY2018Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
346000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
454000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
109000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000
CY2018Q3 us-gaap Depreciation
Depreciation
75000
CY2017Q3 us-gaap Depreciation
Depreciation
11000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1207000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
402000
CY2018Q3 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1733000
CY2017Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
704000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
683000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
103000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53078000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
495000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
31000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9608000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
480049
elox Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
64374
elox Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
68434
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
347241
CY2018Q3 elox Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
347241
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.97
elox Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
0.80
elox Class Of Warrant Or Right Forfeited In Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedInPeriodWeightedAverageExercisePrice
8.00
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.77
CY2018Q3 elox Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice
3.77
CY2017 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y2M26D
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y2M4D
elox Class Of Warrant Or Right Exercisable Expiration Period
ClassOfWarrantOrRightExercisableExpirationPeriod
P4Y2M4D
CY2018Q2 elox Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
2
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3215661
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1637381
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
922524
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
319118
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3611400
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
984975
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.26
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.82
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.54
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M9D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15174026
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28510857
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11573006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.97
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9608000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
elox Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit
10200000
CY2017Q3 elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-802000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-1669000
CY2018Q3 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-11161000
CY2017Q3 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4842000
elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-33158000
elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-12265000
CY2017Q3 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4726384
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20431258
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
elox Number Of Geographic Regions
NumberOfGeographicRegions
2

Files In Submission

Name View Source Status
0001564590-18-028309-index-headers.html Edgar Link pending
0001564590-18-028309-index.html Edgar Link pending
0001564590-18-028309.txt Edgar Link pending
0001564590-18-028309-xbrl.zip Edgar Link pending
elox-10q_20180930.htm Edgar Link pending
elox-20180930.xml Edgar Link completed
elox-20180930.xsd Edgar Link pending
elox-20180930_cal.xml Edgar Link unprocessable
elox-20180930_def.xml Edgar Link unprocessable
elox-20180930_lab.xml Edgar Link unprocessable
elox-20180930_pre.xml Edgar Link unprocessable
elox-ex311_8.htm Edgar Link pending
elox-ex312_6.htm Edgar Link pending
elox-ex321_7.htm Edgar Link pending
elox-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending